{{priceData.date}} {{priceData.time}}
{{'2025-06-20T23:38:25Z' | dateFormatFilter}}
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
{{'2025-06-20T23:34:54Z' | dateFormatFilter}}
Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
{{'2025-06-12T17:06:19Z' | dateFormatFilter}}
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.